Theoharis C Theoharides

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3160740/publications.pdf

Version: 2024-02-01

163	11,882	19636 61	29127 104
papers	citations	h-index	g-index

169	169	169	10837
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mast cells and inflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 21-33.	1.8	627
2	Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical Therapeutics, 2015, 37, 984-995.	1.1	437
3	Corticotropin-Releasing Hormone Induces Skin Mast Cell Degranulation and Increased Vascular Permeability, A Possible Explanation for Its Proinflammatory Effects*. Endocrinology, 1998, 139, 403-413.	1.4	404
4	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 163-172.	13.9	402
5	Critical role of mast cells in inflammatory diseases and the effect of acute stress. Journal of Neuroimmunology, 2004, 146, 1-12.	1.1	392
6	Differential release of mast cell mediators and the pathogenesis of inflammation. Immunological Reviews, 2007, 217, 65-78.	2.8	366
7	Acute Immobilization Stress Triggers Skin Mast Cell Degranulation via Corticotropin Releasing Hormone, Neurotensin, and Substance P: A Link to Neurogenic Skin Disorders. Brain, Behavior, and Immunity, 1999, 13, 225-239.	2.0	324
8	Human Mast Cells Express Corticotropin-Releasing Hormone (CRH) Receptors and CRH Leads to Selective Secretion of Vascular Endothelial Growth Factor. Journal of Immunology, 2005, 174, 7665-7675.	0.4	301
9	Neuroimmunoendocrine circuitry of the â€˜brain-skin connectionâ€™. Trends in Immunology, 2006, 27, 32-39.	2.9	290
10	Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. British Journal of Pharmacology, 2005, 145, 934-944.	2.7	282
11	IL-33 augments substance Pâ€“induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4448-4453.	3.3	282
12	Mast cells as targets of corticotropin-releasing factor and related peptides. Trends in Pharmacological Sciences, 2004, 25, 563-568.	4.0	281
13	The Critical Role of Mast Cells in Allergy and Inflammation. Annals of the New York Academy of Sciences, 2006, 1088, 78-99.	1.8	250
14	Corticotropin-Releasing Hormone and Brain Mast Cells Regulate Blood-Brain-Barrier Permeability Induced by Acute Stress. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1061-1066.	1.3	227
15	IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells. Journal of Immunology, 2003, 171, 4830-4836.	0.4	202
16	Morphological and functional demonstration of rat dura mater mast cellâ€“neuron interactions in vitro and in vivo. Brain Research, 1999, 849, 1-15.	1.1	199
17	Corticotropin-Releasing Hormone and Its Structurally Related Urocortin Are Synthesized and Secreted by Human Mast Cells. Endocrinology, 2004, 145, 43-48.	1.4	174
18	Quercetin Is More Effective than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in Humans. PLoS ONE, 2012, 7, e33805.	1.1	141

#	Article	IF	Citations
19	Focal brain inflammation and autism. Journal of Neuroinflammation, 2013, 10, 46.	3.1	132
20	Longâ€COVID syndromeâ€associated brain fog and chemofog: Luteolin to the rescue. BioFactors, 2021, 47, 232-241.	2.6	128
21	Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7759-7764.	3.3	126
22	Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. Journal of Allergy and Clinical Immunology, 2011, 127, 1522-1531.e8.	1.5	126
23	Mast Cells Regulate Wound Healing in Diabetes. Diabetes, 2016, 65, 2006-2019.	0.3	117
24	Corticotropin-releasing hormone and the blood-brain-barrier. Frontiers in Bioscience - Landmark, 2007, 12, 1615.	3.0	117
25	Perinatal stress, brain inflammation and risk of autism-Review and proposal. BMC Pediatrics, 2012, 12, 89.	0.7	112
26	Brain â€œfog,â€•inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Frontiers in Neuroscience, 2015, 9, 225.	1.4	112
27	The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. Journal of Allergy and Clinical Immunology, 2015, 135, 1044-1052.e5.	1.5	110
28	SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4002-E4009.	3.3	108
29	<scp>COVID</scp>â€19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. BioFactors, 2020, 46, 306-308.	2.6	107
30	Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7049-E7058.	3.3	103
31	Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. British Journal of Pharmacology, 2006, 148, 208-215.	2.7	98
32	Mast cells, brain inflammation and autism. European Journal of Pharmacology, 2016, 778, 96-102.	1.7	98
33	Mast cell activation and autism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 34-41.	1.8	97
34	Stimulated Human Mast Cells Secrete Mitochondrial Components That Have Autocrine and Paracrine Inflammatory Actions. PLoS ONE, 2012, 7, e49767.	1.1	94
35	Serum Interleukin-6 Reflects Disease Severity and Osteoporosis in Mastocytosis Patients. International Archives of Allergy and Immunology, 2002, 128, 344-350.	0.9	93
36	Neuro-Inflammation, Blood-Brain Barrier, Seizures and Autism. Journal of Neuroinflammation, 2011, 8, 168.	3.1	88

#	Article	IF	Citations
37	Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Frontiers in Cellular Neuroscience, 2019, 13, 353.	1.8	86
38	Neurotensin and CRH Interactions Augment Human Mast Cell Activation. PLoS ONE, 2012, 7, e48934.	1.1	84
39	Substance P (SP) Induces Expression of Functional Corticotropin-Releasing Hormone Receptor-1 (CRHR-1) in Human Mast Cells. Journal of Investigative Dermatology, 2012, 132, 324-329.	0.3	83
40	Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 664-672.	1.3	83
41	Neuroendocrinology of mast cells: Challenges and controversies. Experimental Dermatology, 2017, 26, 751-759.	1.4	81
42	Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovascular Research, 2003, 59, 241-249.	1.8	79
43	Acute Stress Results in Skin Corticotropin-Releasing Hormone Secretion, Mast Cell Activation and Vascular Permeability, an Effect Mimicked by Intradermal Corticotropin-Releasing Hormone and Inhibited by Histamine-1 Receptor Antagonists. International Archives of Allergy and Immunology, 2003, 130, 224-231.	0.9	79
44	Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. Journal of Neuroinflammation, 2010, 7, 80.	3.1	79
45	Targeting IL-33 in Autoimmunity and Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 24-31.	1.3	79
46	Recent advances in our understanding of mast cell activation â€“ or should it be mast cell mediator disorders?. Expert Review of Clinical Immunology, 2019, 15, 639-656.	1.3	79
47	Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cellâ€deficient W/W V mice. FASEB Journal, 1998, 12, 1693-1700.	0.2	78
48	Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA, and stimulate human microglia to secrete IL-1Î². Journal of Neuroinflammation, 2018, 15, 239.	3.1	77
49	PENTOSANPOLYSULFATE INHIBITS MAST CELL HISTAMINE SECRETION AND INTRACELLULAR CALCIUM ION LEVELS:: AN ALTERNATIVE EXPLANATION OF ITS BENEFICIAL EFFECT IN INTERSTITIAL CYSTITIS. Journal of Urology, 2000, 164, 2119-2125.	0.2	76
50	Fibromyalgia Syndrome in Need of Effective Treatments. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 255-263.	1.3	76
51	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. Molecular Neurobiology, 2022, 59, 1850-1861.	1.9	76
52	Corticotropin-Releasing Hormone Induces Vascular Endothelial Growth Factor Release from Human Mast Cells via the cAMP/Protein Kinase A/p38 Mitogen-Activated Protein Kinase Pathway. Molecular Pharmacology, 2006, 69, 998-1006.	1.0	73
53	Substance P and IL-33 administered together stimulate a marked secretion of IL-1Î² from human mast cells, inhibited by methoxyluteolin. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9381-E9390.	3.3	73
54	Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clinical Therapeutics, 2018, 40, 903-917.	1.1	72

#	Article	IF	Citations
55	Luteolin as a therapeutic option for multiple sclerosis. Journal of Neuroinflammation, 2009, 6, 29.	3.1	71
56	Exosomes in Neurologic and Psychiatric Disorders. Clinical Therapeutics, 2014, 36, 882-888.	1.1	70
57	Autism: an emerging â€˜neuroimmune disorderâ€™ in search of therapy. Expert Opinion on Pharmacotherapy, 2009, 10, 2127-2143.	0.9	69
58	Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Research, 2003, 980, 213-220.	1.1	67
59	Novel therapeutic targets for autism. Trends in Pharmacological Sciences, 2008, 29, 375-382.	4.0	66
60	Stress triggers coronary mast cells leading to cardiac events. Annals of Allergy, Asthma and Immunology, 2014, 112, 309-316.	0.5	65
61	Neurotensin is increased in serum of young children with autistic disorder. Journal of Neuroinflammation, 2010, 7, 48.	3.1	64
62	Luteolin Inhibits Human Keratinocyte Activation and Decreases NF-ÎºB Induction That Is Increased in Psoriatic Skin. PLoS ONE, 2014, 9, e90739.	1.1	64
63	Contribution of stress to asthma worsening through mast cell activation. Annals of Allergy, Asthma and Immunology, 2012, 109, 14-19.	0.5	62
64	Mast cells in meningiomas and brain inflammation. Journal of Neuroinflammation, 2015, 12, 170.	3.1	62
65	Potential association of mast cells with coronavirus disease 2019. Annals of Allergy, Asthma and Immunology, 2021, 126, 217-218.	0.5	61
66	Autism Spectrum Disorders and Mastocytosis. International Journal of Immunopathology and Pharmacology, 2009, 22, 859-865.	1.0	60
67	Brief Report: â€œAllergic Symptomsâ€•in Children with Autism Spectrum Disorders. More than Meets the Eye?. Journal of Autism and Developmental Disorders, 2011, 41, 1579-1585.	1.7	59
68	Topical Application of a Mast Cell Stabilizer Improves Impaired Diabetic Wound Healing. Journal of Investigative Dermatology, 2020, 140, 901-911.e11.	0.3	58
69	Is a Subtype of Autism an Allergy of the Brain?. Clinical Therapeutics, 2013, 35, 584-591.	1.1	56
70	Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. Journal of Neuroinflammation, 2012, 9, 85.	3.1	55
71	Impact of stress and mast cells on brain metastases. Journal of Neuroimmunology, 2008, 205, 1-7.	1.1	54
72	Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 129, 1410-1413.	1.5	52

#	Article	IF	Citations
73	Mitochondrial Uncoupling Protein 2 Inhibits Mast Cell Activation and Reduces Histamine Content. Journal of Immunology, 2009, 183, 6313-6319.	0.4	50
74	<scp>COVID</scp>â€19, microthromboses, inflammation, and platelet activating factor. BioFactors, 2020, 46, 927-933.	2.6	50
75	Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. Journal of Neuroimmunology, 2015, 279, 33-38.	1.1	49
76	Treatment Approaches for Painful Bladder Syndrome/Interstitial Cystitis. Drugs, 2007, 67, 215-235.	4.9	44
77	Mast cells squeeze the heart and stretch the gird: Their role in atherosclerosis and obesity. Trends in Pharmacological Sciences, 2011, 32, 534-542.	4.0	44
78	IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-ÎºB, inhibited by methoxyluteolin. European Journal of Pharmacology, 2019, 865, 172760.	1.7	43
79	Mast Cells, T Cells, and Inhibition by Luteolin: Implications for the Pathogenesis and Treatment of Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2007, 601, 423-430.	0.8	43
80	The â€œmissing linkâ€•in autoimmunity and autism: Extracellular mitochondrial components secreted from activated live mast cells. Autoimmunity Reviews, 2013, 12, 1136-1142.	2.5	42
81	<scp>TNF</scp> stimulates <scp>IL</scp>â€6, <scp>CXCL</scp>8 and <scp>VEGF</scp> secretion from human keratinocytes via activation of <scp>mTOR</scp>, inhibited by tetramethoxyluteolin. Experimental Dermatology, 2018, 27, 135-143.	1.4	42
82	Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 462-471.	1.3	41
83	Myalgic Encephalomyelitis/Chronic Fatigue Syndromeâ€"Metabolic Disease or Disturbed Homeostasis due to Focal Inflammation in the Hypothalamus?. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 155-167.	1.3	41
84	Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy and Asthma Proceedings, 2018, 39, 153-160.	1.0	41
85	Rupatadine Inhibits Proinflammatory Mediator Secretion from Human Mast Cells Triggered by Different Stimuli. International Archives of Allergy and Immunology, 2010, 151, 38-45.	0.9	40
86	The impact of psychological stress on mast cells. Annals of Allergy, Asthma and Immunology, 2020, 125, 388-392.	0.5	40
87	Mast Cells, Mastocytosis, and Related Disorders. New England Journal of Medicine, 2015, 373, 1884-1886.	13.9	39
88	The Effect of a Herbal Water-Extract on Histamine Release from Mast Cells and on Allergic Asthma. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2003, 3, 41-54.	0.1	38
89	Autism, Gut-Blood-Brain Barrier, and Mast Cells. Journal of Clinical Psychopharmacology, 2008, 28, 479-483.	0.7	38
90	IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21659-21665.	3.3	38

#	Article	IF	Citations
91	Interstitial cystitis: bladder pain and beyond. Expert Opinion on Pharmacotherapy, 2008, 9, 2979-2994.	0.9	36
92	Neuroendocrinology of the skin. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 287-294.	2.6	36
93	Brain Inflammation, Neuropsychiatric Disorders, and Immunoendocrine Effects of Luteolin. Journal of Clinical Psychopharmacology, 2014, 34, 187-189.	0.7	34
94	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. European Journal of Dermatology, 2010, 20, 865-7.	0.3	34
95	Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Annals of Allergy, Asthma and Immunology, 2013, 111, 542-547.	0.5	33
96	Mast Cells, Stress, Fear and Autism Spectrum Disorder. International Journal of Molecular Sciences, 2019, 20, 3611.	1.8	32
97	Mitochondrial dysfunction in affected skin and increased mitochondrial <scp>DNA</scp> in serum from patients with psoriasis. Experimental Dermatology, 2019, 28, 72-75.	1.4	32
98	Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis. Annals of Allergy, Asthma and Immunology, 2007, 98, 269-273.	0.5	30
99	Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37. International Journal of Molecular Sciences, 2019, 20, 3701.	1.8	30
100	Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. British Journal of Haematology, 1998, 103, 798-803.	1.2	28
101	IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16475-16480.	3.3	28
102	Coronavirus 2019, Microthromboses, and Platelet Activating Factor. Clinical Therapeutics, 2020, 42, 1850-1852.	1.1	26
103	Histamine2 (H2)-Receptor Antagonists in the Treatment of Urticaria. Drugs, 1989, 37, 345-355.	4.9	25
104	High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. Journal of Allergy and Clinical Immunology, 2014, 134, 1197-1199.	1.5	24
105	Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. European Journal of Pharmacology, 2018, 818, 294-299.	1.7	24
106	Mast Cells in Irritable Bowel Syndrome and Ulcerative Colitis: Function Not Numbers Is What Makes All the Difference. Digestive Diseases and Sciences, 2014, 59, 897-898.	1.1	23
107	Inhibition of mast cell secretion by oxidation products of natural polyamines. Biochemical Pharmacology, 1992, 43, 2237-2245.	2.0	22
108	Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Tissue and Cell, 2017, 49, 393-400.	1.0	22

#	Article	IF	Citations
109	Nanotube Formation: A Rapid Form of â€œAlarm Signalingâ€?. Clinical Therapeutics, 2016, 38, 1066-1072.	1.1	21
110	Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Canadian Journal of Diabetes, 2018, 42, 568-573.	0.4	21
111	Effect of Stress on Neuroimmune Processes. Clinical Therapeutics, 2020, 42, 1007-1014.	1.1	21
112	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. BioFactors, 2021, 47, 207-217.	2.6	21
113	Danger Signals and Inflammation. Clinical Therapeutics, 2016, 38, 996-999.	1.1	20
114	Brain metastases of mouse mammary adenocarcinoma is increased by acute stress. Brain Research, 2010, 1366, 204-210.	1.1	19
115	Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome. Journal of Neuroinflammation, 2014, 11, 168.	3.1	18
116	Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. International Journal of Immunopathology and Pharmacology, 2017, 30, 146-151.	1.0	18
117	Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by ILâ€33. BioFactors, 2019, 45, 49-61.	2.6	18
118	Increased Expression of miRâ€155p5 in Amygdala of Children With Autism Spectrum Disorder. Autism Research, 2020, 13, 18-23.	2.1	18
119	A probable case report of stress-induced anaphylaxis. Annals of Allergy, Asthma and Immunology, 2014, 112, 383-384.	0.5	17
120	Link between mast cells and bacteria: Antimicrobial defense, function and regulation by cytokines. Medical Hypotheses, 2017, 106, 10-14.	0.8	17
121	ILâ€1B(3954) polymorphism and red complex bacteria increase ILâ€1Î² (GCF) levels in periodontitis. Journal of Periodontal Research, 2021, 56, 501-511.	1.4	17
122	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. International Journal of Molecular Sciences, 2022, 23, 4894.	1.8	17
123	Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). Immunologic Research, 2018, 66, 323-331.	1.3	15
124	Effect of IL-33 on de novo synthesized mediators from human mast cells. Journal of Allergy and Clinical Immunology, 2019, 143, 451.	1.5	15
125	Ways to Address Perinatal Mast Cell Activation and Focal Brain Inflammation, including Response to SARS-CoV-2, in Autism Spectrum Disorder. Journal of Personalized Medicine, 2021, 11, 860.	1.1	15
126	Skin mast cells: are we missing the forest for the trees?. Experimental Dermatology, 2016, 25, 422-423.	1.4	13

#	Article	IF	Citations
127	Stress, Inflammation, and Autoimmunity: The 3 Modern Erinyes. Clinical Therapeutics, 2020, 42, 742-744.	1.1	12
128	Luteolin supplements: All that glitters is not gold. BioFactors, 2021, 47, 242-244.	2.6	12
129	Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases. Current Topics in Medicinal Chemistry, 2019, 18, 1872-1882.	1.0	12
130	Trigeminal nerve stimulation triggers oral mast cell activation and vascular permeability. Annals of Allergy, Asthma and Immunology, 2014, 112, 40-45.	0.5	10
131	Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Immunologic Research, 2017, 65, 982-986.	1.3	10
132	Mast cells participate in allograft rejection: can IL-37 play an inhibitory role?. Inflammation Research, 2018, 67, 747-755.	1.6	10
133	Editorial: Mast Cells in Itch, Pain and Neuro-Inflammation. Frontiers in Cellular Neuroscience, 2019, 13, 521.	1.8	10
134	Interstitial Cystitis and Bladder Mastocytosis in a Woman with Chronic Urticaria. Scandinavian Journal of Urology and Nephrology, 1997, 31, 497-500.	1.4	9
135	A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 4480.	1.8	9
136	Genitourinary mast cells and survival. Translational Andrology and Urology, 2015, 4, 579-86.	0.6	9
137	Successful Treatment of a Patient With Severe COVID-19 Using an Integrated Approach Addressing Mast Cells and Their Mediators. International Journal of Infectious Diseases, 2022, 118, 164-166.	1.5	9
138	Effect of stress on learning and motivation-relevance to autism spectrum disorder. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841985676.	1.0	8
139	Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells. Molecular and Cellular Biochemistry, 1996, 155, 61-68.	1.4	7
140	Vitamin D and Atopy. Clinical Therapeutics, 2017, 39, 880-883.	1.1	7
141	Amyotrophic Lateral Sclerosis, Neuroinflammation, and Cromolyn. Clinical Therapeutics, 2020, 42, 546-549.	1.1	7
142	Mast cells promote malaria infection?. Clinical Therapeutics, 2015, 37, 1374-1377.	1.1	6
143	Luteolin: The wonder flavonoid. BioFactors, 2021, 47, 139-140.	2.6	6
144	Antihistamines and Mental Status. Journal of Clinical Psychopharmacology, 2016, 36, 195-197.	0.7	5

#	Article	IF	Citations
145	Meta-Analysis and Bioinformatics Detection of Susceptibility Genes in Diabetic Nephropathy. International Journal of Molecular Sciences, 2022, 23, 20.	1.8	5
146	Effects of an Extract of Salmon Milt on Symptoms and Serum TNF and Substance P in Patients With Fibromyalgia Syndrome. Clinical Therapeutics, 2019, 41, 1564-1574.e2.	1.1	4
147	Substance P and Hemokinin 1Âin Nasal Lavage Fluid of Patients with Chronic Sinusitis and Nasal Polyposis. OTO Open, 2019, 3, 2473974X19875076.	0.6	4
148	Mast cells to dendritic cells: Let IL-13 shut your IL-12 down. Journal of Allergy and Clinical Immunology, 2021, 147, 2073-2074.	1.5	4
149	Post-Lyme Syndromeâ€"Associated Polyneuropathy Treated With Immune Immunoglobulin and a Luteolin-Containing Formulation. Journal of Clinical Psychopharmacology, 2016, 36, 290-291.	0.7	3
150	A Timely Multidisciplinary Update on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 610-611.	1.1	3
151	The Effect of a Herbal Water-Extract on Histamine Release from Mast Cells and on Allergic Asthma. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2003, 3, 41-54.	0.1	3
152	Intimate Contact Could Be Dangerous for Your Health. Clinical Therapeutics, 2019, 41, 1222-1226.	1.1	2
153	Need to define a subgroup of patients with idiopathic mast cell activation syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1127-1128.	2.0	2
154	On the Gut Microbiome-Brain Axis and Altruism. Clinical Therapeutics, 2015, 37, 937-940.	1.1	1
155	Nasal cytology with emphasis on mast cells can improve the diagnosis and treatment of chronic rhinosinusitis. Chinese Medical Journal, 2019, 132, 2237-2241.	0.9	1
156	ExoProK: A Practical Method for the Isolation of Small Extracellular Vesicles from Pleural Effusions. Methods and Protocols, 2021, 4, 31.	0.9	1
157	Luteolin inhibits human cultured keratinocyte inflammatory cytokine release and proliferation. FASEB Journal, 2013, 27, lb564.	0.2	1
158	Immune-Related Gene Polymorphisms and Pharmacogenetic Studies in Nephrology. Clinical Therapeutics, 2021, 43, 2148-2153.	1.1	1
159	Reply to Fattori et al.: Action of SP and IL-33 on mast cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10036-E10036.	3.3	0
160	IgE and macrophages for cancer rescue?. EBioMedicine, 2019, 43, 7-8.	2.7	0
161	In Search of Effective Treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 796-797.	1.1	0
162	Uncoupling protein 2 regulates mast cell activation. FASEB Journal, 2008, 22, 1139.1.	0.2	0

#	Article	IF	Citations
163	Human mast cell degranulation is distinguished from selective secretion of TNF through intracellular calcium, energy and mitochondrial morphology dynamics. FASEB Journal, 2010, 24, 966.3.	0.2	0